KALVKalVista Pharmaceuticals, Inc.

KALV Stock Price, Valuation & Chart | KalVista Pharmaceuticals, Inc.

Compare

$27.000+0.00 (+0.00%)

At close · 10 June 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology KALV intrinsic value Is KALV overvalued or undervalued

Overview Financials Dividends Ratios

KALV Historical price chart

KALV Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization1.44B

PE Ratio-6.85

EPS-3.94

Trading Volume4.26M

Today's High/Low27.0/26.98

Dividend Yield0.00

52 Week High/Low27.0/9.83

Shares Outstanding53.24M

KALV Financial Statement

KALV Analyst ratings

KALV Analysis & performance metrics

KALV Company profile

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet…

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products…

KALV Management team

Name

Position

Brian Krex J.D.

General Counsel

Christopher M. Yea Ph.D.

Chief Development Officer

Paul K. Audhya M.B.A., M.D.

Chief Medical Officer

Jarrod Aldom

Vice President of Corporate Communications

Ryan Baker

Head of Investor Relations

Jeb LedellCOO

Chief Operating Officer

Brian PiekosCFO

Chief Financial Officer

Michael D. Smith Pharm.D.

Senior Vice President of Development

Name

Position

Brian Krex J.D.

General Counsel

Christopher M. Yea Ph.D.

Chief Development Officer

Paul K. Audhya M.B.A., M.D.

Chief Medical Officer

Jarrod Aldom

Vice President of Corporate Communications

Ryan Baker

Head of Investor Relations

Jeb LedellCOO

Chief Operating Officer

Brian PiekosCFO

Chief Financial Officer

Michael D. Smith Pharm.D.

Senior Vice President of Development

Management Team

Brian Krex J.D.

General Counsel

Christopher M. Yea Ph.D.

Chief Development Officer

Paul K. Audhya M.B.A., M.D.

Chief Medical Officer

Jarrod Aldom

Vice President of Corporate Communications

Ryan Baker

Head of Investor Relations

Jeb LedellCOO

Chief Operating Officer

Brian PiekosCFO

Chief Financial Officer

Michael D. Smith Pharm.D.

Senior Vice President of Development

Management

Brian Krex J.D.

General Counsel

Christopher M. Yea Ph.D.

Chief Development Officer

Paul K. Audhya M.B.A., M.D.

Chief Medical Officer

Jarrod Aldom

Vice President of Corporate Communications

Ryan Baker

Head of Investor Relations

Jeb LedellCOO

Chief Operating Officer

Brian PiekosCFO

Chief Financial Officer

Michael D. Smith Pharm.D.

Senior Vice President of Development

Total 8 executives

KALV Frequently asked questions

What is KalVista Pharmaceuticals, Inc. (KALV) Stock Price?

Current stock price of KalVista Pharmaceuticals, Inc. (KALV) stock is $27.000. The stock price is +0.00% higher in the session. The intraday range can be seen from this page. Volume of KalVista Pharmaceuticals, Inc. (KALV) stock is 4.26M.

Last updated at 10 June 2026, 08:00 pm.

Why is the KalVista Pharmaceuticals, Inc. (KALV) stock price going up or down today?

The stock price of KalVista Pharmaceuticals, Inc. (KALV) can change with earnings, company news, and overall market sentiment. KalVista Pharmaceuticals, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the KalVista Pharmaceuticals, Inc. stock expensive at its current price?

Whether KalVista Pharmaceuticals, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for KALV on this page is -6.85. EPS on this page is -3.94. Compare those figures with peers and growth expectations before deciding if the current KalVista Pharmaceuticals, Inc. price is justified.

How has the stock price of KalVista Pharmaceuticals, Inc. (KALV) performed historically?

Historical performance for KalVista Pharmaceuticals, Inc. (KALV) is shown on the price chart on this page. Review multi-period moves alongside volume to see how KALV reacted to past earnings and market events.

Should I buy KalVista Pharmaceuticals, Inc. (KALV) stock, at this price?

Buying KalVista Pharmaceuticals, Inc. (KALV) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.